Cancer Articles
A new study shows melanoma forms resistance against the MAPK inhibitors that are commonly used to treat it, while at the same time actively suppressing the immune cells that would otherwise help eliminate it.
New clinical trial results show a personalized mRNA-based melanoma vaccine, intismeran, significantly reduces the risk of cancer recurrence or death within two years.
The Food and Drug Administration has approved atezolizumab in combination with fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 2 years of age and older with stage III mismatch repair deficient colon cancer
A Phase III trial evaluating adjuvant treatment with intismeran autogene in combination with KEYTRUDA (pembrolizumab) showed positive results in treating patients with completely resected stage IIB-IV melanoma.
FDA has approved Tregzi, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation.
A study has found the combination of a vaccine and a drug, which both harness the immune system to attack cancer cells, is successful in cutting the risk of skin cancer recurrence and death by 49 percent.
The U.S. Food and Drug Administration has approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA (pembrolizumab).
A clinical tria that evaluated an alpha-lactalbumin (aLA) vaccine demonstrated an immune response in 74 percent of patients who presently have or are at high risk for triple-negative breast cancer.
Researchers have developed an inhalable nanotherapy called BEAT (Bispecific Exosome Activator of T Cells) that can activate the immune system against cancers resistant to current checkpoint inhibitor therapies.
The U.S. Department of Health and Human Services has doubled funding for its Childhood Cancer Data Initiative at the National Institutes of Health
The U.S. Food and Drug Administration has approved KEYTRUDA and KEYTRUDA QLEX in combination with Padcev, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Researchers re-engineered the structure of the commonly ussed chemotherapy drug 5-fluorouracil (5FU) into that of a “spherical nucleic acid” — a nanostructure that weaves the drug directly into DNA strands coating tiny spheres, making its cancer cell-killing ability 20,000 more effective, while also reducing its toxicity.